Analyst Ratings For PTC Therapeutics (NASDAQ:PTCT)
Today, William Blair reiterated its Hold rating on PTC Therapeutics (NASDAQ:PTCT).
Some recent analyst ratings include
- 3/7/2018-William Blair Reiterated Rating of Hold.
- 1/30/2018-Credit Suisse Group Reiterated Rating of Buy.
- 1/29/2018-Royal Bank of Canada initiated coverage with a Sector Perform rating.
- 1/23/2018-Barclays Reiterated Rating of Hold.
- 10/26/2017-Bank of America was Downgraded by analysts at Bank of America from a “Neutral ” rating to a ” Underperform” rating.
Recent Insider Trading Activity For PTC Therapeutics (NASDAQ:PTCT)
PTC Therapeutics (NASDAQ:PTCT) has insider ownership of 8.10% and institutional ownership of 91.87%.
- On 1/5/2018 Stuart Walter Peltz, CEO, sold 2,230 with an average share price of $18.03 per share and the total transaction amounting to $40,206.90.
- On 1/4/2018 Christine Marie Utter, Insider, sold 412 with an average share price of $17.67 per share and the total transaction amounting to $7,280.04.
- On 1/4/2018 Neil Gregory Almstead, EVP, sold 77 with an average share price of $17.67 per share and the total transaction amounting to $1,360.59.
- On 5/23/2017 Dawn Svoronos, Director, bought 25,000 with an average share price of $13.49 per share and the total transaction amounting to $337,250.00.
- On 1/5/2017 Neil Gregory Almstead, EVP, sold 78 with an average share price of $11.82 per share and the total transaction amounting to $921.96.
- On 3/3/2016 Mark Rothera, Insider, bought 2,000 with an average share price of $6.23 per share and the total transaction amounting to $12,460.00.
- On 7/6/2015 David P Southwell, Director, sold 23,604 with an average share price of $47.52 per share and the total transaction amounting to $1,121,662.08.
Recent Trading Activity for PTC Therapeutics (NASDAQ:PTCT)
Shares of PTC Therapeutics closed the previous trading session at 29.84 up +3.00 11.20% with shares trading hands.
